<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The β-blocker <z:chebi fb="2" ids="8499">propranolol</z:chebi>, originally designed for cardiological indications (<z:mp ids='MP_0006112'>angina</z:mp>, <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and <z:mp ids='MP_0002842'>high blood pressure</z:mp>), is nowadays, considered the most efficient drug for the treatment in <z:e sem="disease" ids="C0206733" disease_type="Neoplastic Process" abbrv="">infantile haemangiomas</z:e> (IH), a <z:e sem="disease" ids="C0282607" disease_type="Neoplastic Process" abbrv="">vascular tumour</z:e> that affects 5-10% of <z:hpo ids='HP_0000001'>all</z:hpo> infants </plain></SENT>
<SENT sid="1" pm="."><plain>However, its potential therapeutic benefits in other vascular anomalies remain to be explored </plain></SENT>
<SENT sid="2" pm="."><plain>In the present work we have assessed the impact of <z:chebi fb="2" ids="8499">propranolol</z:chebi> in endothelial cell cultures to test if this drug could be used in the <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> hereditary haemorrhagic <z:hpo ids='HP_0001009'>telangiectasia</z:hpo> (HHT) </plain></SENT>
<SENT sid="3" pm="."><plain>This <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> is the result of <z:mp ids='MP_0000260'>abnormal angiogenesis</z:mp> with <z:hpo ids='HP_0000421'>epistaxis</z:hpo>, mucocutaneous and gastrointestinal <z:hpo ids='HP_0001009'>telangiectases</z:hpo>, as well as <z:hpo ids='HP_0100026'>arteriovenous malformations</z:hpo> in several organs, as clinical manifestations </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations in Endoglin (ENG) and ACVLR1 (ALK1) genes, lead to HHT1 and HHT2, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Endoglin and ALK1 are involved in the TGF-β1 signalling pathway and play a critical role for the proper development of the blood vessels </plain></SENT>
<SENT sid="6" pm="."><plain>As HHT is due to a deregulation of key angiogenic factors, inhibitors of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> have been used to normalise the nasal vasculature eliminating <z:hpo ids='HP_0000421'>epistaxis</z:hpo> derived from <z:hpo ids='HP_0001009'>telangiectases</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, the antiangiogenic properties of <z:chebi fb="2" ids="8499">propranolol</z:chebi> were tested in endothelial cells </plain></SENT>
<SENT sid="8" pm="."><plain>The drug was able to decrease cellular migration and tube formation, concomitantly with reduced <z:chebi fb="40" ids="33697">RNA</z:chebi> and protein levels of ENG and ALK1 </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, the drug showed apoptotic effects which could explain cell <z:hpo ids='HP_0011420'>death</z:hpo> in IH </plain></SENT>
<SENT sid="10" pm="."><plain>Interestingly, <z:chebi fb="2" ids="8499">propranolol</z:chebi> showed some profibrinolytic activity, decreasing PAI-1 levels </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that local administration of <z:chebi fb="2" ids="8499">propranolol</z:chebi> in the nose mucosa to control <z:hpo ids='HP_0000421'>epistaxis</z:hpo> might be a potential therapeutic approach in HHT </plain></SENT>
</text></document>